BIOTECHNOLOGY company Silence Therapeutics has appointed Tim Freeborn as FD.
Freeborn qualified as a chartered accountant with Arthur Goddard & Co, specialising in corporate tax. He then spent 12 years as a finance journalist at the Daily Mail before spending two years editing the Penny Shares Guide. He also wrote part-time for Shares Magazine.
In 2004, Freeborn joined Evolution Securities as an analyst, focusing on renewables and alternative energy, before he joined Xcap Securities in 2009, becoming head of research.
“Silence’s area of biotech is moving incredibly quickly. The company could play a big role and I’m delighted to be joining at this time,” he said.
Former chief executive of HMRC Dame Lin Homer has been appointed to the ICAS council as a public interest member
Andrew Tyrie airs views on the Finance Bill, 'Making Tax Policy Better' report, and Brexit
After a seven-year saga, a result has been reached between Margaret May and CIMA over misconduct
Top 25 firm HW Fisher & Co has acquired London firm Rhodes & Rhodes